Cemiplimab for the first-line treatment of patients wth advanced or metastatic PD-L1 positive non-small-cell lung cancer

NICE

1 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of cemiplimab in the NHS in England.

NICE is unable to make a recommendation on the use of cemiplimab for the first-line treatment of adults with PD-L1 positive advanced or metastatic non-small-cell lung cancer because Sanofi did not provide an evidence submission.

Read NICE technology appraisal

Michael Wonder

Posted by:

Michael Wonder